img

Global Liposome Finished Pharmaceuticals Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Liposome Finished Pharmaceuticals Market Research Report 2024

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
According to Mr Accuracy reports’s new survey, global Liposome Finished Pharmaceuticals market is projected to reach US$ 9855.2 million in 2029, increasing from US$ 5019 million in 2022, with the CAGR of 10.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Liposome Finished Pharmaceuticals market research.
The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market's potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Liposome Finished Pharmaceuticals market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs

Segment by Application


Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Liposome Finished Pharmaceuticals report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liposome Finished Pharmaceuticals Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Liposomes Drugs
1.2.3 Lipid Nanoparticle Drugs
1.3 Market by Application
1.3.1 Global Liposome Finished Pharmaceuticals Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposome Finished Pharmaceuticals Market Perspective (2018-2029)
2.2 Liposome Finished Pharmaceuticals Growth Trends by Region
2.2.1 Global Liposome Finished Pharmaceuticals Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Liposome Finished Pharmaceuticals Historic Market Size by Region (2018-2024)
2.2.3 Liposome Finished Pharmaceuticals Forecasted Market Size by Region (2024-2029)
2.3 Liposome Finished Pharmaceuticals Market Dynamics
2.3.1 Liposome Finished Pharmaceuticals Industry Trends
2.3.2 Liposome Finished Pharmaceuticals Market Drivers
2.3.3 Liposome Finished Pharmaceuticals Market Challenges
2.3.4 Liposome Finished Pharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposome Finished Pharmaceuticals Players by Revenue
3.1.1 Global Top Liposome Finished Pharmaceuticals Players by Revenue (2018-2024)
3.1.2 Global Liposome Finished Pharmaceuticals Revenue Market Share by Players (2018-2024)
3.2 Global Liposome Finished Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Liposome Finished Pharmaceuticals Revenue
3.4 Global Liposome Finished Pharmaceuticals Market Concentration Ratio
3.4.1 Global Liposome Finished Pharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposome Finished Pharmaceuticals Revenue in 2022
3.5 Liposome Finished Pharmaceuticals Key Players Head office and Area Served
3.6 Key Players Liposome Finished Pharmaceuticals Product Solution and Service
3.7 Date of Enter into Liposome Finished Pharmaceuticals Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposome Finished Pharmaceuticals Breakdown Data by Type
4.1 Global Liposome Finished Pharmaceuticals Historic Market Size by Type (2018-2024)
4.2 Global Liposome Finished Pharmaceuticals Forecasted Market Size by Type (2024-2029)
5 Liposome Finished Pharmaceuticals Breakdown Data by Application
5.1 Global Liposome Finished Pharmaceuticals Historic Market Size by Application (2018-2024)
5.2 Global Liposome Finished Pharmaceuticals Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Liposome Finished Pharmaceuticals Market Size (2018-2029)
6.2 North America Liposome Finished Pharmaceuticals Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Liposome Finished Pharmaceuticals Market Size by Country (2018-2024)
6.4 North America Liposome Finished Pharmaceuticals Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposome Finished Pharmaceuticals Market Size (2018-2029)
7.2 Europe Liposome Finished Pharmaceuticals Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Liposome Finished Pharmaceuticals Market Size by Country (2018-2024)
7.4 Europe Liposome Finished Pharmaceuticals Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposome Finished Pharmaceuticals Market Size (2018-2029)
8.2 Asia-Pacific Liposome Finished Pharmaceuticals Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Liposome Finished Pharmaceuticals Market Size by Region (2018-2024)
8.4 Asia-Pacific Liposome Finished Pharmaceuticals Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposome Finished Pharmaceuticals Market Size (2018-2029)
9.2 Latin America Liposome Finished Pharmaceuticals Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Liposome Finished Pharmaceuticals Market Size by Country (2018-2024)
9.4 Latin America Liposome Finished Pharmaceuticals Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposome Finished Pharmaceuticals Market Size (2018-2029)
10.2 Middle East & Africa Liposome Finished Pharmaceuticals Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Liposome Finished Pharmaceuticals Market Size by Country (2018-2024)
10.4 Middle East & Africa Liposome Finished Pharmaceuticals Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Liposome Finished Pharmaceuticals Introduction
11.1.4 Johnson & Johnson Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.1.5 Johnson & Johnson Recent Development
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Detail
11.2.2 Sun Pharmaceutical Business Overview
11.2.3 Sun Pharmaceutical Liposome Finished Pharmaceuticals Introduction
11.2.4 Sun Pharmaceutical Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.2.5 Sun Pharmaceutical Recent Development
11.3 CSPC
11.3.1 CSPC Company Detail
11.3.2 CSPC Business Overview
11.3.3 CSPC Liposome Finished Pharmaceuticals Introduction
11.3.4 CSPC Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.3.5 CSPC Recent Development
11.4 Kinyond
11.4.1 Kinyond Company Detail
11.4.2 Kinyond Business Overview
11.4.3 Kinyond Liposome Finished Pharmaceuticals Introduction
11.4.4 Kinyond Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.4.5 Kinyond Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva Liposome Finished Pharmaceuticals Introduction
11.5.4 Teva Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.5.5 Teva Recent Development
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Detail
11.6.2 Fudan-Zhangjiang Business Overview
11.6.3 Fudan-Zhangjiang Liposome Finished Pharmaceuticals Introduction
11.6.4 Fudan-Zhangjiang Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.6.5 Fudan-Zhangjiang Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Detail
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Liposome Finished Pharmaceuticals Introduction
11.7.4 Zydus Cadila Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.7.5 Zydus Cadila Recent Development
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Detail
11.8.2 TTY Biopharma Business Overview
11.8.3 TTY Biopharma Liposome Finished Pharmaceuticals Introduction
11.8.4 TTY Biopharma Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.8.5 TTY Biopharma Recent Development
11.9 Pacira
11.9.1 Pacira Company Detail
11.9.2 Pacira Business Overview
11.9.3 Pacira Liposome Finished Pharmaceuticals Introduction
11.9.4 Pacira Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.9.5 Pacira Recent Development
11.10 Luye Pharma
11.10.1 Luye Pharma Company Detail
11.10.2 Luye Pharma Business Overview
11.10.3 Luye Pharma Liposome Finished Pharmaceuticals Introduction
11.10.4 Luye Pharma Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.10.5 Luye Pharma Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Detail
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Liposome Finished Pharmaceuticals Introduction
11.11.4 Leadiant Biosciences Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.11.5 Leadiant Biosciences Recent Development
11.12 Ipsen
11.12.1 Ipsen Company Detail
11.12.2 Ipsen Business Overview
11.12.3 Ipsen Liposome Finished Pharmaceuticals Introduction
11.12.4 Ipsen Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.12.5 Ipsen Recent Development
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Detail
11.13.2 Sayre Therapeutics Business Overview
11.13.3 Sayre Therapeutics Liposome Finished Pharmaceuticals Introduction
11.13.4 Sayre Therapeutics Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.13.5 Sayre Therapeutics Recent Development
11.14 Jazz
11.14.1 Jazz Company Detail
11.14.2 Jazz Business Overview
11.14.3 Jazz Liposome Finished Pharmaceuticals Introduction
11.14.4 Jazz Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.14.5 Jazz Recent Development
11.15 Alnylam
11.15.1 Alnylam Company Detail
11.15.2 Alnylam Business Overview
11.15.3 Alnylam Liposome Finished Pharmaceuticals Introduction
11.15.4 Alnylam Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.15.5 Alnylam Recent Development
11.16 Bausch Health
11.16.1 Bausch Health Company Detail
11.16.2 Bausch Health Business Overview
11.16.3 Bausch Health Liposome Finished Pharmaceuticals Introduction
11.16.4 Bausch Health Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.16.5 Bausch Health Recent Development
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Detail
11.17.2 Acrotech Biopharma Business Overview
11.17.3 Acrotech Biopharma Liposome Finished Pharmaceuticals Introduction
11.17.4 Acrotech Biopharma Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.17.5 Acrotech Biopharma Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Liposome Finished Pharmaceuticals Introduction
11.18.4 Takeda Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.18.5 Takeda Recent Development
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Detail
11.19.2 Chiesi Farmaceutici Business Overview
11.19.3 Chiesi Farmaceutici Liposome Finished Pharmaceuticals Introduction
11.19.4 Chiesi Farmaceutici Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.19.5 Chiesi Farmaceutici Recent Development
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Detail
11.20.2 Gilead Sciences Business Overview
11.20.3 Gilead Sciences Liposome Finished Pharmaceuticals Introduction
11.20.4 Gilead Sciences Revenue in Liposome Finished Pharmaceuticals Business (2018-2024)
11.20.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Liposome Finished Pharmaceuticals Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Liposomes Drugs
Table 3. Key Players of Lipid Nanoparticle Drugs
Table 4. Global Liposome Finished Pharmaceuticals Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Liposome Finished Pharmaceuticals Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Liposome Finished Pharmaceuticals Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Liposome Finished Pharmaceuticals Market Share by Region (2018-2024)
Table 8. Global Liposome Finished Pharmaceuticals Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Liposome Finished Pharmaceuticals Market Share by Region (2024-2029)
Table 10. Liposome Finished Pharmaceuticals Market Trends
Table 11. Liposome Finished Pharmaceuticals Market Drivers
Table 12. Liposome Finished Pharmaceuticals Market Challenges
Table 13. Liposome Finished Pharmaceuticals Market Restraints
Table 14. Global Liposome Finished Pharmaceuticals Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Liposome Finished Pharmaceuticals Market Share by Players (2018-2024)
Table 16. Global Top Liposome Finished Pharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposome Finished Pharmaceuticals as of 2022)
Table 17. Ranking of Global Top Liposome Finished Pharmaceuticals Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Liposome Finished Pharmaceuticals Revenue (CR5 and HHI) & (2018-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Liposome Finished Pharmaceuticals Product Solution and Service
Table 21. Date of Enter into Liposome Finished Pharmaceuticals Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Liposome Finished Pharmaceuticals Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Liposome Finished Pharmaceuticals Revenue Market Share by Type (2018-2024)
Table 25. Global Liposome Finished Pharmaceuticals Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Liposome Finished Pharmaceuticals Revenue Market Share by Type (2024-2029)
Table 27. Global Liposome Finished Pharmaceuticals Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Liposome Finished Pharmaceuticals Revenue Market Share by Application (2018-2024)
Table 29. Global Liposome Finished Pharmaceuticals Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Liposome Finished Pharmaceuticals Revenue Market Share by Application (2024-2029)
Table 31. North America Liposome Finished Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Liposome Finished Pharmaceuticals Market Size by Country (2018-2024) & (US$ Million)
Table 33. North America Liposome Finished Pharmaceuticals Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Liposome Finished Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Liposome Finished Pharmaceuticals Market Size by Country (2018-2024) & (US$ Million)
Table 36. Europe Liposome Finished Pharmaceuticals Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Liposome Finished Pharmaceuticals Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Liposome Finished Pharmaceuticals Market Size by Region (2018-2024) & (US$ Million)
Table 39. Asia-Pacific Liposome Finished Pharmaceuticals Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Liposome Finished Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Liposome Finished Pharmaceuticals Market Size by Country (2018-2024) & (US$ Million)
Table 42. Latin America Liposome Finished Pharmaceuticals Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Liposome Finished Pharmaceuticals Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Liposome Finished Pharmaceuticals Market Size by Country (2018-2024) & (US$ Million)
Table 45. Middle East & Africa Liposome Finished Pharmaceuticals Market Size by Country (2024-2029) & (US$ Million)
Table 46. Johnson & Johnson Company Detail
Table 47. Johnson & Johnson Business Overview
Table 48. Johnson & Johnson Liposome Finished Pharmaceuticals Product
Table 49. Johnson & Johnson Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 50. Johnson & Johnson Recent Development
Table 51. Sun Pharmaceutical Company Detail
Table 52. Sun Pharmaceutical Business Overview
Table 53. Sun Pharmaceutical Liposome Finished Pharmaceuticals Product
Table 54. Sun Pharmaceutical Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 55. Sun Pharmaceutical Recent Development
Table 56. CSPC Company Detail
Table 57. CSPC Business Overview
Table 58. CSPC Liposome Finished Pharmaceuticals Product
Table 59. CSPC Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 60. CSPC Recent Development
Table 61. Kinyond Company Detail
Table 62. Kinyond Business Overview
Table 63. Kinyond Liposome Finished Pharmaceuticals Product
Table 64. Kinyond Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 65. Kinyond Recent Development
Table 66. Teva Company Detail
Table 67. Teva Business Overview
Table 68. Teva Liposome Finished Pharmaceuticals Product
Table 69. Teva Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 70. Teva Recent Development
Table 71. Fudan-Zhangjiang Company Detail
Table 72. Fudan-Zhangjiang Business Overview
Table 73. Fudan-Zhangjiang Liposome Finished Pharmaceuticals Product
Table 74. Fudan-Zhangjiang Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 75. Fudan-Zhangjiang Recent Development
Table 76. Zydus Cadila Company Detail
Table 77. Zydus Cadila Business Overview
Table 78. Zydus Cadila Liposome Finished Pharmaceuticals Product
Table 79. Zydus Cadila Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 80. Zydus Cadila Recent Development
Table 81. TTY Biopharma Company Detail
Table 82. TTY Biopharma Business Overview
Table 83. TTY Biopharma Liposome Finished Pharmaceuticals Product
Table 84. TTY Biopharma Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 85. TTY Biopharma Recent Development
Table 86. Pacira Company Detail
Table 87. Pacira Business Overview
Table 88. Pacira Liposome Finished Pharmaceuticals Product
Table 89. Pacira Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 90. Pacira Recent Development
Table 91. Luye Pharma Company Detail
Table 92. Luye Pharma Business Overview
Table 93. Luye Pharma Liposome Finished Pharmaceuticals Product
Table 94. Luye Pharma Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 95. Luye Pharma Recent Development
Table 96. Leadiant Biosciences Company Detail
Table 97. Leadiant Biosciences Business Overview
Table 98. Leadiant Biosciences Liposome Finished Pharmaceuticals Product
Table 99. Leadiant Biosciences Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 100. Leadiant Biosciences Recent Development
Table 101. Ipsen Company Detail
Table 102. Ipsen Business Overview
Table 103. Ipsen Liposome Finished Pharmaceuticals Product
Table 104. Ipsen Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 105. Ipsen Recent Development
Table 106. Sayre Therapeutics Company Detail
Table 107. Sayre Therapeutics Business Overview
Table 108. Sayre Therapeutics Liposome Finished Pharmaceuticals Product
Table 109. Sayre Therapeutics Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 110. Sayre Therapeutics Recent Development
Table 111. Jazz Company Detail
Table 112. Jazz Business Overview
Table 113. Jazz Liposome Finished Pharmaceuticals Product
Table 114. Jazz Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 115. Jazz Recent Development
Table 116. Alnylam Company Detail
Table 117. Alnylam Business Overview
Table 118. Alnylam Liposome Finished Pharmaceuticals Product
Table 119. Alnylam Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 120. Alnylam Recent Development
Table 121. Bausch Health Company Detail
Table 122. Bausch Health Business Overview
Table 123. Bausch Health Liposome Finished Pharmaceuticals Product
Table 124. Bausch Health Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 125. Bausch Health Recent Development
Table 126. Acrotech Biopharma Company Detail
Table 127. Acrotech Biopharma Business Overview
Table 128. Acrotech Biopharma Liposome Finished Pharmaceuticals Product
Table 129. Acrotech Biopharma Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 130. Acrotech Biopharma Recent Development
Table 131. Takeda Company Detail
Table 132. Takeda Business Overview
Table 133. Takeda Liposome Finished Pharmaceuticals Product
Table 134. Takeda Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 135. Takeda Recent Development
Table 136. Chiesi Farmaceutici Company Detail
Table 137. Chiesi Farmaceutici Business Overview
Table 138. Chiesi Farmaceutici Liposome Finished Pharmaceuticals Product
Table 139. Chiesi Farmaceutici Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 140. Chiesi Farmaceutici Recent Development
Table 141. Gilead Sciences Company Detail
Table 142. Gilead Sciences Business Overview
Table 143. Gilead Sciences Liposome Finished Pharmaceuticals Product
Table 144. Gilead Sciences Revenue in Liposome Finished Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 145. Gilead Sciences Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Liposome Finished Pharmaceuticals Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Liposome Finished Pharmaceuticals Market Share by Type: 2022 VS 2029
Figure 3. Liposomes Drugs Features
Figure 4. Lipid Nanoparticle Drugs Features
Figure 5. Global Liposome Finished Pharmaceuticals Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 6. Global Liposome Finished Pharmaceuticals Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Other Case Studies
Figure 10. Liposome Finished Pharmaceuticals Report Years Considered
Figure 11. Global Liposome Finished Pharmaceuticals Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Liposome Finished Pharmaceuticals Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Liposome Finished Pharmaceuticals Market Share by Region: 2022 VS 2029
Figure 14. Global Liposome Finished Pharmaceuticals Market Share by Players in 2022
Figure 15. Global Top Liposome Finished Pharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposome Finished Pharmaceuticals as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Liposome Finished Pharmaceuticals Revenue in 2022
Figure 17. North America Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Liposome Finished Pharmaceuticals Market Share by Country (2018-2029)
Figure 19. United States Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Liposome Finished Pharmaceuticals Market Share by Country (2018-2029)
Figure 23. Germany Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Liposome Finished Pharmaceuticals Market Share by Region (2018-2029)
Figure 31. China Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Liposome Finished Pharmaceuticals Market Share by Country (2018-2029)
Figure 39. Mexico Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Liposome Finished Pharmaceuticals Market Share by Country (2018-2029)
Figure 43. Turkey Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Liposome Finished Pharmaceuticals Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Johnson & Johnson Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 46. Sun Pharmaceutical Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 47. CSPC Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 48. Kinyond Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 49. Teva Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 50. Fudan-Zhangjiang Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 51. Zydus Cadila Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 52. TTY Biopharma Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 53. Pacira Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 54. Luye Pharma Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 55. Leadiant Biosciences Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 56. Ipsen Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 57. Sayre Therapeutics Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 58. Jazz Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 59. Alnylam Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 60. Bausch Health Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 61. Acrotech Biopharma Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 62. Takeda Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 63. Chiesi Farmaceutici Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 64. Gilead Sciences Revenue Growth Rate in Liposome Finished Pharmaceuticals Business (2018-2024)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries